Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VINC) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for oncology, with a primary emphasis on hematologic malignancies and solid tumors. The company entered public markets through a merger with LifeSci Acquisition Corp., a blank-check vehicle sponsored by LifeSci Acquisition Sponsor, LLC that completed its IPO in 2019. The business combination closed in December 2020, listing Vincerx under the VINC ticker. The company filed an 8-K with the SEC on July 7, 2025, reporting a material corporate event under standard Exchange Act disclosure requirements. For complete filing history, deal analytics, and real-time SPAC data on Vincerx and hundreds of other transactions, sign up for full access at SpacDesk.